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Abstract
The PLZF/RARA fusion protein generated by the t(11;17)(q23;q21) translocation in acute promyelocytic leukaemia (APL) is
believed to act as an oncogenic transcriptional regulator recruiting epigenetic factors to genes important for its
transforming potential. However, molecular mechanisms associated with PLZF/RARA-dependent leukaemogenesis still
remain unclear. We searched for specific PLZF/RARA target genes by ChIP-on-chip in the haematopoietic cell line U937
conditionally expressing PLZF/RARA. By comparing bound regions found in U937 cells expressing endogenous PLZF with
PLZF/RARA-induced U937 cells, we isolated specific PLZF/RARA target gene promoters. We next analysed gene expression
profiles of our identified target genes in PLZF/RARA APL patients and analysed DNA sequences and epigenetic modification
at PLZF/RARA binding sites. We identify 413 specific PLZF/RARA target genes including a number encoding transcription
factors involved in the regulation of haematopoiesis. Among these genes, 22 were significantly down regulated in primary
PLZF/RARA APL cells. In addition, repressed PLZF/RARA target genes were associated with increased levels of H3K27me3
and decreased levels of H3K9K14ac. Finally, sequence analysis of PLZF/RARA bound sequences reveals the presence of both
consensus and degenerated RAREs as well as enrichment for tissue-specific transcription factor motifs, highlighting the
complexity of targeting fusion protein to chromatin. Our study suggests that PLZF/RARA directly targets genes important
for haematopoietic development and supports the notion that PLZF/RARA acts mainly as an epigenetic regulator of its
direct target genes.
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Introduction
Retinoic acid receptors (RARs) belong to a family of nuclear
receptors that can activate or repress transcription of target genes
by recruiting co-activator or co-repressor complexes. It is the
binding of its natural ligand, retinoic acid (RA), which transforms
the activity of RAR from a repressor to an activator of trans-
cription by inducing a conformational change in the ligand
binding domain structure [1,2]. In acute promyelocytic leukaemia
(APL), the RAR alpha (RARA) gene on chromosome 17, finds itself
involved in chromosomal recombination with one of several
different potential partner genes (designated ‘‘X’’), i.e. PML, PLZF,
NuMA, NPM1, FIP1L1, PRKAR1A, STAT5b or BCOR, generating
X/RARA fusion proteins [3,4]. Evidence to date suggests that X/
RARA induces a characteristic block in differentiation, associated
with the APL phenotype through repression of downstream target
genes [1–4]. The capacity of X/RARAs to form homo-oligomers
and hetero-oligomers has been proven critical for inducing
transformation and defines their oncogenic propensity [5–8].
However, it is still not well understood the extent to which the X/
RARA protein, as part of an oligomeric complex, has acquired
altered DNA-binding capacity that may result in aberrant
expression of genes normally (or not) regulated by wild-type
RARA. Several studies have suggested that the presence of the
partner X enforces a different conformation of the DNA
recognition site for X/RARA versus RARA and that X/RARA
would recognise degenerate RA response elements [8–10]. This
phenomenon could be amplified by recruitment of co-factors that
may also impose and/or change the DNA recognition specificity
[11].
PLoS ONE | www.plosone.org 1 September 2011 | Volume 6 | Issue 9 | e24176The nature of the fusion partner X has a decisive impact on the
disease state and sensitivity to the therapeutic effects of all-trans RA
(ATRA) and arsenic trioxide (ATO) [12]. Importantly, PLZF/
RARA-associated APL is resistant to ATO and exhibits impaired
sensitivity to ATRA, giving rise to a significantly poorer clinical
outcome compared to patients with classical PML-RARA+
disease, which typically responds to both of these molecularly-
targeted therapies [13,14]. Studies conducted over a decade ago
provided insights into the distinct natural history of these subtypes
of APL, showing major differences in the capacity of the PML/
RARA and PLZF/RARA fusion proteins to bind corepressor
complexes according to the level of retinoic acid. While
corepressors are displaced from the PML/RARA oncoprotein in
the presence of pharmacological doses of retinoid, binding of
SMRT/NCoR-HDAC [15,16] and epigenetic factors such as
Polycomb group (PcG) complexes [17] to PLZF/RARA persists
under such conditions through interaction with the PLZF moiety
of the fusion protein [18]. These specific recruitments provide an
explanation for the ATRA-resistant phenotype and suggest there
may be mechanistic differences in transcriptional repression
mediated by PLZF/RARA as compared to other X/RARA
fusions. Due to the PLZF moiety, PLZF/RARA could potentially
control two different sets of genes: those genes normally regulated
by RARA-RXR and those that are de novo target genes due to the
Figure 1. Genome-wide identification of PLZF/RARA-binding sites using ChIP-on-chip (a) ChIP-on-chip profiles of PLZF(/RARA)
binding along the HOXD gene cluster on chromosome 2 in U937 and U937-PLZF/RARA cell lines as indicated in the figure. The plots
show the log2 ratio of PLZF ChIP over the INPUT, combined from two independent experiments. Positions of the genes are shown under the profiles.
(b) ChIP-qPCR PLZF fold enrichment on CDKN1A, HOXD9 and HOXD4 promoters in the absence or in the presence of PLZF/RARA. (c) Zoomed-in
view of PLZF binding at 11 selected promoters as indicated, showing differences upon PLZF/RARA induction. (d) PLZF/RARA fold enrichment was
measured for the selected promoters by ChIP-qPCR in PLZF/RARA expressing cells.
doi:10.1371/journal.pone.0024176.g001
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situation is made more complicated by expression of the reciprocal
RARA/PLZF that can potentially bind to PLZF binding sites
where it may function as a transcriptional activator [19]. The
development of genome-wide approaches such as ChIP-on-chip
has favoured the identification of genomic targets that have
widened our understanding of oncogenic transcription factor
activities.
Here, we report a genome-wide ChIP-on-chip study of PLZF/
RARA gene targets using an inducible cell system. We identify 413
high-confidence specific target genes that provide clues as to how
PLZF/RARA contributes to APL pathogenesis.
Results and Discussion
Genome-wide identification of specific PLZF/RARA target
genes
To identify gene targets directly regulated by PLZF/RARA, we
took advantage of a zinc-inducible U937 cell system either
expressing the PLZF/RARA fusion protein or harbouring an
empty vector [20]. In the U937-B412 cell line, PLZF/RARA
expression can be induced upon zinc induction (Figure S1). We
performed ChIP experiments using an anti-PLZF antibody that
recognises both wild-type PLZF and the PLZF/RARA fusion
protein. Immunoprecipitated DNA samples were hybridised to a
custom promoter array containing ,18,000 human promoters
and replicate experiments were merged (see Materials and
Methods). Using a peak detection algorithm [21] we identified a
total of 1545 significantly bound promoter regions in the U937-
PLZF/RARA cell line. Among these targets, we found previously
characterised PLZF targets, such as several genes from the HOXD
cluster [17,22] (Figure 1a). Indeed, we detected high enrichment
signals at the promoter regions of the HOXD4 and HOXD9 genes
in both U937-PLZF/RARA and control cell lines. These data
were corroborated by quantitative PCR analyses of independent
PLZF ChIP samples (ChIP-qPCR) (Figure 1b). To identify PLZF/
RARA-specific target genes we compared the targets found in the
zinc-stimulated U937-PLZF/RARA cell line to those found in the
zinc-stimulated control U937-empty vector cell line and identified
412 promoter regions that were significantly bound only upon
PLZF/RARA induction (Table S1). Among these genes, we
identified RARB2 (the RARA fusion model target gene) as well as
C/EBPE, ASB2, PRAM1 and IL8, that have all previously been
reported to be regulated by X/RARA fusion proteins [23–26]. To
further validate the specificity of our approach, we performed
quantitative PCR analyses on ChIP samples (ChIP-qPCR) on a
selection of ten PLZF/RARA specific target genes and one
negative control (Fig. 1c). All tested PLZF/RARA–bound pro-
moter regions were significantly amplified in the induced U937-
PLZF/RARA cell line only (Fig. 1d), underscoring the specificity
of the generated PLZF/RARA-binding profiles.
In a recent study, Rice and colleagues [26] identified more
than 4900 genes as direct PLZF and/or PLZF/RARA targets.
However, in this work the PLZF and PLZF/RARA targets were
not discriminated, making it difficult to compare with the specific
PLZF/RARA targets identified in the present study. Nevertheless,
168 specific PLZF/RARA target genes from our study were also
identify as potential targets in the Rice study. The discrepancies
between the two studies might be explained by the different
experimental procedures and by the methods and the thresholds
used to select bona-fide binding regions. Functional classification of
specific PLZF/RARA target genes according to gene ontology
(GO) analyses showed that PLZF/RARA binds to genes
implicated in either basic cellular processes or developmental
related processes (Table 1). Strikingly, a significant number of the
gene products are involved in the regulation of transcription,
highlighting the oncogenic potential that could arise from their
deregulation, including transcription factors implicated in haema-
topoietic development, such as C/EBPA, C/EBPE, GATA1 and
BCL6, as well as other general chromatin modifiers such as BRD2,
MBD6 and SMARCD2 (Table 2).
Gene expression changes at PLZF/RARA target genes
To determine the transcriptional effect of PLZF/RARA on its
identified target genes, gene expression profiling was performed
in U937-MT (control) and U937-B412 (PLZF/RARA) cell lines.
Expression profiling following PLZF/RARA induction was
evaluated by microarray analysis and 4321 genes were identified
with altered expression levels (.1.5 fold; P,0.05). A highly
significant 20% of the genes targeted by PLZF/RARA have
altered expression patterns (P=4.99 610
29, Fisher exact) with 11%
becoming down regulated and 9% being up regulated upon
PLZF/RARA binding (Figure 2a). This result is consistent with
previous microarray analyses that have revealed that PLZF/
RARA induces a signature characterised by both down regulated
and up regulated genes [24,26]. This suggests that while PLZF/
RARA can act as a transcriptional regulator, effects of PLZF/
RARA binding to chromatin cannot be measured only by
transcriptional analysis. In addition, this shows that the direct
transcriptional activity of PLZF/RARA is difficult to assess in an
established cell line that has already shut down transcriptional
pathways. To analyze the significance of PLZF/RARA targets
identified by ChIP-on-chip with the APL phenotype we
performed analyses of microarray gene-expression profiles from
diagnostic samples from PLZF/RARA+ patients. These analyses
identified 22 direct PLZF/RARA target genes that were signifi-
cantly down regulated inPLZF/RARAAPLblastsimplicating their
deregulation in tumour pathogenesis (Figure 2b). The analysis
confirmed that the ITGB2 gene encoding CD18, which is
characteristically under expressed in primary APL cells (a feature
used to help identify patients with PML-RARA+ disease) [27], was
also down regulated in the presence of the PLZF/RARA fusion.
Moreover,wedemonstrated that several PLZF/RARA-targetgenes
relevant for malignant haematopoiesis were significantly down
regulated in PLZF/RARA patient samples, including IDH2, PAX5
and DAZAP1. IDH2 is frequently mutated in acute myeloid
leukaemia and its mutations confer adverse prognosis in cytogenet-
icallynormalAML[28,29].PAX5and DAZAP1arebothinvolvedin
translocations associated with acute lymphoblastic leukaemia
[30,31]. In addition, PLZF/RARA significantly down regulated
Table 1. Gene ontology analysis of PLZF/RARA direct target
genes.
Biological process Count % P-Value
Signal transduction 80 23.70% 1.70e-05
Cell motility 24 7.10% 5.50e-05
Protein phosphorylation 50 14.80% 6.50e-05
mRNA transcription regulation 153 45.30% 1.40e-04
Fatty acid beta-oxidation 10 3.00% 1.80e-04
mRNA transcription 101 29.90% 1.30e-03
Protein modification 53 15.70% 1.70e-03
Cell proliferation and differentiation 26 7.70% 2.60e-03
doi:10.1371/journal.pone.0024176.t001
Characterization of Genome-Wide PLZF/RARA Targets
PLoS ONE | www.plosone.org 3 September 2011 | Volume 6 | Issue 9 | e24176Table 2. PLZF/RARA selected target genes.
Regulation of transcription
CEBPE CCAAT/enhancer binding protein epsilon RARE
RARB Retinoic acid receptor, beta RARE
TRIM38 Tripartite motif-containing 38 RARE
TBX20 T-box 20
CEBPA CCAAT/enhancer binding protein (C/EBP), alpha
RGS12 Regulator of G-protein signaling 12 RARE
BIN1 Bridging integrator 1
EGLN2 Egl nine homolog 2 (C. elegans) RARE
GTPBP3 GTP binding protein 3 (mitochondrial) RARE
DDIT3 DNA-damage-inducible transcript 3 RARE
FOS V-fos FBJ osteosarcoma viral oncogene homolog
MEOX2 Mesenchyme homeobox 2
BCL3 B-cell CLL/lymphoma 3 RARE
GATA1 GATA binding protein 1 RARE
CDKN1C Cyclin-dependent kinase inhibitor 1C (p57, Kip2)
BHLHB2 Basic helix-loop-helix domain containing class B 2 RARE
BCL6 B-cell CLL/lymphoma 6 (zinc finger protein 51)
BCL11A B-cell CLL/lymphoma 11A (zinc finger protein) RARE
LMO2 LIM domain only 2 (rhombotin-like 1)
CSDA Cold shock domain protein A RARE
FOXP1 Forkhead box P1 RARE
SKIL SKI-like oncogene RARE
SMARCD2 SWI/SNF related, subfamily d, member 2 RARE
ETV5 Ets variant gene 5 (ets-related molecule) RARE
FHL1 Four and a half LIM domains 1
POU4F3 POU class 4 homeobox 3
AIRE Autoimmune regulator
LPXN Leupaxin RARE
CDCA7L Cell division cycle associated 7-like RARE
BRD2 Bromodomain containing 2 RARE
ZFP91 Zinc finger protein 91 homolog (mouse) RARE
ETV1 Ets variant gene 1 RARE
RORC RAR-related orphan receptor C RARE
SOX12 SRY (sex determining region Y)-box 12 RARE
POU3F3 POU class 3 homeobox 3
MBD6 Methyl-CpG binding domain protein 6 RARE
Neuron development/cell morphogenesis
MAP1B Microtubule-associated protein 1B
LST1 Leukocyte specific transcript 1
AXUD1 AXIN1 up-regulated 1 RARE
NGRN Neugrin, neurite outgrowth associated RARE
Signal transduction
ARHGAP12 Rho GTPase activating protein 12
PLEKHH2 Pleckstrin domain containing, family H member 2 RARE
GAB1 GRB2-associated binding protein 1
STAP2 Signal transducing adaptor family member 2 RARE
OSBPL8 Oxysterol binding protein-like 8
PRAM1 PML-RARA regulated adaptor molecule 1 RARE
Signal transduction
IL8 Interleukin 8
TGFB1 Transforming growth factor, beta 1
Post-translational protein modification
CDKN1C Cyclin-dependent kinase inhibitor 1C (p57, Kip2)
CDK5 Cyclin-dependent kinase 5 RARE
ASB2 Ankyrin repeat and SOCS box-containing 2 RARE
UBE4B Ubiquitination factor E4B (UFD2 homolog, yeast) RARE
DAPK3 Death-associated protein kinase 3
ITPKB Inositol 1,4,5-trisphosphate 3-kinase B
PFKP Phosphofructokinase, platelet RARE
SNRK SNF related kinase RARE
MAP3K8 Mitogen-activated protein kinase kinase kinase 8 RARE
PKN2 Protein kinase N2
CASP8 Caspase 8, apoptosis-related cysteine peptidase
TBL1XR1 Transducin (beta)-like 1X-linked receptor 1
HECW1 E3 ubiquitin protein ligase 1 RARE
RBKS RIBOKINASE RARE
DUSP4 Dual specificity phosphatase 4 RARE
DUSP6 Dual specificity phosphatase 6 RARE
PLCB2 Phospholipase C, beta 2 RARE
PLCD3 Phospholipase C, delta 3
Mitochondrion
PDP2 Pyruvate dehydrogenase phosphatase isoenzyme 2 RARE
MRPL54 Mitochondrial ribosomal protein L54 RARE
MTRF1L Mitochondrial translational release factor 1-like RARE
NDUFA4 NADH dehydrogenase 1 alpha subcomplex, 4, 9 kDa RARE
MTX1 Metaxin 1 RARE
Magmas Mitochondria-associated protein
Integral/Intrinsic to Membrane
DHRS3 Dehydrogenase/reductase (SDR family) member 3 RARE
CD38 CD38 molecule RARE
IL21R Interleukin 21 receptor RARE
GPR81 G protein-coupled receptor 81
SERPINE1 Serpin peptidase inhibitor, clade E RARE
SERPINB6 Serpin peptidase inhibitor, clade B, member 6
ICAM1 Intercellular adhesion molecule 1 (CD54) RARE
THBS3 Thrombospondin 3 RARE
TCIRG1 T-cell, immune regulator 1, lysosomal V0 subunit A3 RARE
KAZALD1 Kazal-type serine peptidase inhibitor domain 1 RARE
DLL3 Delta-like 3 (Drosophila)
DLL4 Delta-like 4 (Drosophila)
SYT3 Synaptotagmin III RARE
SCAMP4 Secretory carrier membrane protein 4 RARE
MOXD1 Monooxygenase, DBH-like 1
ITGB2 Integrin beta 2 (CD18) RARE
LTB Lymphotoxin beta (TNF superfamily, member 3) RARE
AGTRAP Angiotensin II receptor-associated protein RARE
IL4I1 Interleukin 4 Induced 1 RARE
Table 2. Cont.
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growth factor beta-1 (TGFbeta-1), a pluripotent cytokine that
controls key tumour suppressive functions. Interestingly, cytoplas-
mic PML has been described as a critical TGF-beta regulator and
PML/RARA APL cells have defects in TGF-beta signalling similar
to those observed in PML-null cells [32,33]. This is also the case for
DUSP6, an inhibitor of the ERK signalling that has been described
to be under expressed in different types of cancer, including
pancreatic [34] and lung cancer [35], and which was reported as a
potential PLZF-RARA target gene by Rice and colleagues [26].
The expression profiles obtained with the patient samples
correlates with the expression profile obtained in B412 cell system
as the majority of the genes down regulated in PLZF/RARA+
patients were also down regulated in B412 cells expressing PLZF/
RARA (Figure 2c). This integrated genome wide analysis thus
highlights the importance of a subset of PLZF/RARA target genes
and reveals new pathways that could be disrupted in the PLZF/
RARA APL.
Chromatin modification at PLZF/RARA target genes
PLZF/RARA was shown to act as a dominant-negative
inhibitor of RARA, mediating repression of retinoid target genes
important for myeloid differentiation: PLZF/RARA binding to
RARB2 has previously been shown to recruit PcG complexes,
leading to an increase in trimethylation of Lysine 27 of histone H3
(H3K27me3) and RARB2 repression (ref. [17] and data not
shown). To investigate whether PLZF/RARA can induce
chromatin modification at its target genes, we analysed the
trimethylation status of lysines 4 and 27 of histone H3 (H3K4me3
and H3K27me3) and the acetylation status of histone H3
(H3K9K14Ac) in response to PLZF/RARA-induction by ChIP-
on-chip. Indeed, PLZF/RARA induction provokes epigenetic
variations represented as an increase in H3K27me3, a decrease in
H3K4me3 or a decrease in H3K9K14Ac on 267 of its 413 target
genes (Figure 3a). To evaluate the consequences of epigenetic
changes on gene expression, we calculated the percentages of
deregulated genes in function of individual or combinatorial
changes for each histone modification (Figure 3b). We observed
that the correlation between histone modifications and gene
expression changes was higher when taking into account at least 2
of the analysed marks. Strikingly, genes displaying epigenetic
changes for all three of the histone modifications displayed the
higher percentage of repressed genes. These results strongly
support the idea that PLZF/RARA protein could recruit different
co-repressor complexes to its target gene promoters, resulting in a
multiplicity of epigenetic changes.
To validate the transcriptional and epigenetic effects of PLZF/
RARA on its identified target genes, we analysed the mRNA
expression level as well as changes in epigenetic histone
modifications of a subset of PLZF/RARA targets. The five
selected genes were repressed by direct PLZF/RARA binding,
while their epigenetic changes were showing similar characteristics
(Figure 4). With the exception of ASB2, the genes down regulated
by PLZF/RARA recruitment display an increase in H3K27me3 at
their promoters with a concomitant decrease in H3K9K14Ac
(Figure 4). H3K4me3 was either decreased or unmodified but was
not found increased at PLZF/RARA repressed loci (Figure 4).
Interestingly, ITGB2 and IL8 that are strongly repressed in B412
cell line and that display epigenetic changes for the 3 histone
modifications (Figure 4), were down regulated in PLZF/RARA+
patient (Figure 2). These observations emphasize the importance
of these two genes in APL pathology and highlight the relevance of
epigenetic changes consistent with a PcG-repressed chromatin
state that is mediated by PLZF/RARA binding.
In this study we show that PLZF/RARA expression induces
epigenetic changes in a subset of genes of which expression is not
necessarily modified. This observation is interesting in the context
of the different nature of the fusion partner X that impact on the
therapeutic effects of ATRA and ATO. Previous studies have
demonstrated that X/RARA proteins recruit different partners
that exert influences upon disease characteristics with respect to
sensitivity to RA treatment [15–18]. In this study we reveal an
epigenetic profile that is characteristic to PLZF/RARA bound
loci. While a study has shown that high levels of H3K27me3 was
associated with the PML/RARA binding region in the RARB2
promoter [36], genome-wide analysis of H3K27me3 at PML/
RARA binding sites reveals no significant increase of this rep-
ressive mark related to PML/RARA induction [3]. Thus,
characterisation of epigenetic changes induced by X/RARA,
even if not associated with detectable changes in gene expression,
could provide an explanation for the difference in sensitivity to
RA.
Sequence analysis of the PLZF/RARA-bound DNA
PLZF/RARA has conserved the DNA binding domain of
RARA that binds to RA response elements (RAREs) defined by a
direct repeat of the core motif 59-RGKTCA-39 separated by 1, 2
or 5 nucleotides (DR1, DR2, DR5) [9]. To determine whether the
core motif RGKTCA (RARE half-site or RAREh) was the
determining factor in recruiting PLZF/RARA, the sequences
overlapping each peak were analyzed for the presence of this
motif. We found that approximately half (233 out of 412) of the
PLZF/RARA-bound DNA sequences contained at least one
RAREh and that among these DNA sequences, almost 50% of
them contained two or more repeats of the RAREh (Figure 5a).
Spacing and orientation of core motifs dictate the specificity of
DNA recognition by the nuclear receptors and the X/RARA
fusion proteins [37]. We analysed for the presence of the possible
combination of the core motif sequence; direct repeat (DR),
inverse repeat (IR) or everted repeat (ER) in PLZF/RARA
promoters where we could detect more than one RAREh. This
showed that binding more frequently occurs at DR elements than
at IR or ER motifs, with DR1, DR2 and DR5 accounting for 35%
of promoter sites targeted by PLZF/RARA overall (Figure 5b).
Thus, PLZF/RARA appears to bind to promoter regions har-
bouring either consensus or highly degenerated RARE, but the
presence of RAREs is not absolutely required for PLZF/RARA to
bind to its target promoters. However, we could not find a
correlation between the presence of RARE in PLZF/RARA
binding sites and PLZF/RARA target gene expression (Table S1).
This result confirms previous observations suggesting that the
binding of X/RARA to chromatin does not require direct
consensus RARE [37]. This is due to the presence of the fusion
Integral/Intrinsic to Membrane
FLOT1 Flotillin 1 RARE
MAN1C1 Mannosidase, alpha, class 1C, member 1 RARE
TNFSF4 Tumor necrosis factor member 4 RARE
MEGF11 Multiple EGF-like-domains 11
FAM69A FAMILY WITH SEQUENCE SIMILARITY 69 RARE
HIGD1A HIG1 domain family, member 1A RARE
doi:10.1371/journal.pone.0024176.t002
Table 2. Cont.
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response elements beyond those bound by native RARA [39]. The
binding of PLZF/RARA to promoter regions in the absence of
RAREh suggests that other factors influence PLZF/RARA
chromatin targeting. For example, chromatin structure could
influence PLZF/RARA targeting. A recent genome-wide study
showed that even in the case of wild-type RARA, DR1, DR2 or
DR5 elements do not account for the majority of bound loci,
proposing that chromatin topology contributes to RAR occupancy
[38]. A potential difference between PLZF as a fusion partner and
most of the other APL fusion partners (e.g. PML) is that PLZF can
bind DNA in its own right. Although the PLZF DNA binding
Figure 2. Expression profile of PLZF/RARA target genes. (a) Analysis of variations in PLZF/RARA-direct target gene expression after PLZF/RARA
induction in the B412 cell line. (b) Heat map representing mRNA expression levels of PLZF/RARA-direct target genes in PLZF/RARA positive APL
samples and normal bone marrow (NBM) samples. Relative expression levels are normalized across the samples; levels greater than or less than the
mean are shown in shades of red and blue, respectively. (c) Changes in expression of the 23 genes identified in (b) in response to PLZF/RARA
induction in U937-B412 cells. The differential gene expression corresponds to the difference of microarray fluorescence intensity between MT and
B412 cell lines for the indicated genes.
doi:10.1371/journal.pone.0024176.g002
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PLZF/RARA could be targeted to PLZF binding sites. In order to
find out whether significant binding sites can be identified in
PLZF/RARA bound regions we searched for transcription factor
(TF) binding sites using Genomatix (Table 3 and Figure S2). We
found that PLZF/RARA target regions were significantly enriched
for several TF binding sites, including the KLF and ETS family of
TFs. However, we did not find that PLZF/RARA target regions
were specifically enriched for PLZF binding sites. Interestingly,
PML/RARA was recently shown to be targeted to genes regulated
by PU.1, a member of the ETS family [4]. Thus, it is possible that
like PML/RARA, PLZF/RARA collaborates with other tissue-
specific TFs for DNA binding.
Conclusion
By comparing PLZF bound regions between U937 and PLZF/
RARA-induced U937 cells we identified 413 specific PLZF/RARA
target genes. This selection of bona-fide PLZF/RARA targets was
significantly enriched in genes important for hematopoietic deve-
lopment and included genes effectively downregulated in primary
PLZF/RARA+ APL cells. Moreover, PLZF/RARA binding was
preferentially associated with gene repression at sites enriched for
the repressive H3K27me3 histone modification mark. Analysis of
PLZF/RARA bound sequences suggests PLZF/RARA binds
canonical and degenerate RARE motifs, and recruitment of
PLZF/RARA may also occur via other hematopoietic specific
TFs. This study helps to clarify the role of the PLZF/RARA fusion
protein as an oncogenic transcriptional regulator during leukaemo-
genesis and provides further insights into the pathogenesis of the
disease.
Materials and Methods
Cell lines
Human myelomonoblastic cell lines U937-MT and U937-B412
[20] were maintained at exponential growth in RPMI supple-
mented with 10% foetal calf serum. U937-MT is the empty vector
control, U937-B412 contains PLZF/RARA cDNA under the
control of the zinc inducible human-metallothionein promoter
[20]. For PLZF/RARA induction cells were prestimulated with
0.1 mM ZnSO4 for at least 24 h.
RNA isolation and RT-PCR
Total RNA was extracted using the RNeasy Mini kit according
to the manufacturer’s protocol (Qiagen), For cDNA synthesis,
reverse transcription was performed with 2 mg of the total RNA,
oligo dT, dNTPs, DTT, buffer and Superscript Retrotranscriptase
II (Invitrogen). cDNA was analyzed by qPCR using Brilliant
Figure 3. Chromatin modifications at PLZF/RARA target genes. (a) Venn diagram representing the combinatorial changes of histone
modifications at PLZF/RARA target genes. The total number of PLZF/RARA target gene promoters displaying decreased levels of H3K14ac or
H3K4me3, or increased levels of H3K27me3 is also indicated. (b) The bar plot indicates the percentages of either repressed or induced genes,
accordingly to the combinatorial changes of histone modifications. The percentages are relative to gene numbers indicated in Figure 3a.
doi:10.1371/journal.pone.0024176.g003
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turer’s instructions with the 7500 Fast Real Time PCR system
(Applied Biosystems). Primers used for real-time PCR are given in
Supporting Information.
ChIP
Chromatin Immunoprecipitation (ChIP) was essentially per-
formed as described before by Boukarabila et al. [17]. U937 Cells
were treated with 1% formaldehyde (RT, 10 min), and chromatin
was extracted then sonicated for 15 min using a Diagenode
Bioruptor (full power, 30 s on 30 s off). For ChIP using PLZF
antibody, (H300; Santa Cruz), chromatin extracted from 1610
7
cells per condition was used. For ChIP using H3K27me3 (Abcam,
ab6002), H3K4me3 (Diagenode, pAB-003-050) or H3K9K14Ac
(Millipore, 06-599), chromatin from 5610
6 cells per condition was
used. Chromatin was diluted 56in 150 mM NaCl, 10 mM Tris-
HCl pH 8.0, 1% TritonX-100, 0.1% sodium deoxycholate
(NaDOC), 1 mM EDTA, 0.5 mM EGTA. Chromatin, precleared
1 h with protein G-coupled magnetic beads, was incubated
overnight at 4uC using the different antibodies followed by an
incubation for 2 h with blocked protein G-coupled magnetic beads
(Dynabeads, Invitrogen). Real-time PCR was performed using
Brilliant SYBR Green Master Mix (Stratagene) according to the
manufacturer’s instructions with the 7500 Fast Real Time PCR
system (Applied Biosystems). Primers used are given in Text S1.
ChIP-on-chip
Total DNA and ChIP DNA were amplified using the whole
genome amplification kit (WGA-2, Sigma-Aldrich, Taufkirchen,
Germany) and fluorescently labelled using BioPrime Array CGH
Genomic labelling kit (Invitrogen). Labeled samples were
hybridized following the manufacturer’s instructions to a custom
Figure 4. Validation of gene expression and chromatin modification changes at PLZF/RARA target genes. Zinc-induced U937-MT cells
(light grey bars) or U937-B412 cells (dark grey bars) were analysed as follows. For mRNA expression level, RNA was extracted and reverse-transcribed;
the selected target genes were analyzed by qRT-PCR. Gene expression of each gene is shown relative to HPRT expression. For epigenetic marks,
H3K27me3, H3K4me3 and H3Ac were analysed by ChIP-qPCR at the indicated promoter.
doi:10.1371/journal.pone.0024176.g004
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probes spanning the promoter regions (22,5 kb to +1k b ) o f
18.000 refseq genes (UCSC assembly HG17). Experiments were
performed in duplicate and showed high correlation (R$0.769).
All data is MIAME compliant. Median-normalized log2 enrich-
ment ratios (ChIP/Input) of merged replicates were calculated
using CoCAS software [21]. For PLZF ChIP-on-chip experi-
ments, significantly enriched promoters were isolated using the
peak detection algorithm in CoCAS and the following settings:
26 and 16 standard deviations for main and extended
thresholds, respectively. Enrichment scores were calculated by
measuring the effective peak area [21]. For histone modification
experiments, enrichment scores were calculated by computing the
average signals at each promoter region. Next, fold changes
between MT and B412 chromatin at PLZF/RARA target
promoters were calculated for each epigenetic mark. Gene
promoters displaying a differential enrichment of .0,135 (P
val,0.05) for a given histone modification, were considered to be
differentially marked.
Functional annotation of genes
Target genes were classified using DAVID [39] and according
to PANTHER molecular functions and biological process
categories. Only the highest significant categories were selected
(P,0,001).
Sequence analysis
We looked for the consensus RARE motif using Perl regular
expressions (http://www.perl.org) on ChIP-on-chip peak sequenc-
es. The expression code was built according to the known repeat
pattern (A/G)G(G/T)TCA. We allowed a gap ranging from 0 to
100 bases and performed the calculation for finding DR, IR and
ER on both strands. Analyses of transcription factor binding site
enrichments were performed using MatInspector tool from
GENOMATIX software (http://www.genomatix.de).
Microarray analysis
MT and B412 cells were cultured in duplicate in the presence of
zinc for 48 hours. RNA was extracted using QIAGEN RNeasy
and quality was tested using an Agilent Bioanalyzer. 1 mg of RNA
was hybridized to U133 Plus 2.0 arrays (Affymetrix). Affymetrix
U133A.CEL data files from B412 cells and MT cells were
imported into R and probe intensities were normalized using GC-
RMA. A total of 4321 genes were found to be differentially
expressed (.1,5 fold; P,0.05). For patient samples, microarray
raw data was taken from Gene Expression Omnibus (http://www.
Figure 5. Presence of RARE in PLZF/RARA target promoters. (a) Percentage of PLZF/RARA bound regions containing 0, 1, 2, and 3 or more the
core motif RGKTCA or RARE half site (RAREh). (b) PLZF/RARA target regions were scanned for the presence of Direct (DR), Inverse (IR) or Everted (ER)
RARE repeats with a maximum spacer length of 13 nucleotides. The % of target promoters as a function of spacer length is plotted.
doi:10.1371/journal.pone.0024176.g005
Table 3. Transcription factor matrix families over-represented in PLZF/RARA target regions*.
TF Families Description Number of Sequences
Overepresentation
(promoters) Z-Score (promoters)
V$KLFS Krueppel like transcription factors 327 1,71 21,17
V$ETSF Human and murine ETS1 factors 327 1,23 6,51
V$EGRF EGR/nerve growth factor induced protein
C & related factors
321 2,22 34,33
V$ZBPF Zinc binding protein factors 318 2,23 36,84
V$SP1F GC-Box factors SP1/GC 312 2,08 28,06
V$CTCF CTCF and BORIS gene family 305 2,3 29,94
V$RXRF RXR heterodimer binding sites 286 1,19 4,76
*The most frequent matrix families are shown.
doi:10.1371/journal.pone.0024176.t003
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primary PLZF/RARA+ APL patient cases and under the data set
GSE15061 for normal bone marrow samples (NBM). Details of
the patient samples analysed have been reported previously [19].
Expression data were Robust Multichip Average (RMA) [40]
normalised using the ‘affy’ R/Bioconductor library. The differen-
tial gene expression study was performed by Significance Analysis
of Microarrays using MeV software [41].
Supporting Information
Figure S1 Expression of PLZF/RARA, PLZF and RARA
proteins in MT and B412 cell lines. Nuclear extracts were
prepared from U937-MT (1) and U937-B412 (2) treated with zinc
and were immunobloted for PLZF/RARA and PLZF (a-PLZF) or
RARA (a-RARA).
(TIF)
Figure S2 Transcription factor binding sites over-
represented in PLZF/RARA target promoters. MatInspec-
tor tool from GENOMATIX was used to identified transcription
binding sites in PLZF/RARA bound promoters.
(TIF)
Table S1 List of PLZF/RARA target genes. Indicated in
the table are symbols and full names of PLZF/RARA target genes,
the presence, number and type of RAREh in PLZF/RARA
enriched peak and micro array data of PLZF/RARA target genes.
Diff mean corresponds to the difference of the mean between MT
and B412 cell lines.
(XLSB)
Text S1 Supplemental experimental procedures.
(DOCX)
Acknowledgments
We thank the Technological Advances for Genomics and Clinics (TAGC)
platform for providing access to the microarray scanner. We thank Pascal
Finetti for technical help.
Author Contributions
Conceived and designed the experiments: BC MS PF SS ED. Performed
the experiments: GT TB CV-F AJS JZ-C SS ED. Analyzed the data: SS
ED AJS DG. Contributed reagents/materials/analysis tools: FB DG KM.
Wrote the paper: SS ED.
References
1. Scaglioni PP, Pandolfi PP (2007) The theory of APL revisited. Curr Top
Microbiol Immunol 313: 85–100.
2. Hoemme C, Peerzada A, Behre G, Wang Y, McClelland M, et al. (2008)
Chromatin modifications induced by PML-RARalpha repress critical targets in
leukemogenesis as analyzed by ChIP-Chip. Blood 111: 2887–2895.
3. Martens JH, Brinkman AB, Simmer F, Francoijs KJ, Nebbioso A, et al. (2010)
PML-RARalpha/RXR Alters the Epigenetic Landscape in Acute Promyelocytic
Leukemia. Cancer Cell 17: 173–185.
4. Wang K, Wang P, Shi J, Zhu X, He M, et al. (2010) PML/RARalpha targets
promoter regions containing PU.1 consensus and RARE half sites in acute
promyelocytic leukemia. Cancer Cell 17: 186–197.
5. Salomoni P, Pandolfi PP (2000) Transcriptional regulation of cellular
transformation. Nat Med 6: 742–744.
6. Kwok C, Zeisig BB, Dong S, So CW (2006) Forced homo-oligomerization of
RARalpha leads to transformation of primary hematopoietic cells. Cancer Cell
9: 95–108.
7. Sternsdorf T, Phan VT, Maunakea ML, Ocampo CB, Sohal J, et al. (2006)
Forced retinoic acid receptor alpha homodimers prime mice for APL-like
leukemia. Cancer Cell 9: 81–94.
8. Zhou J, Peres L, Honore N, Nasr R, Zhu J, et al. (2006) Dimerization-induced
corepressor binding and relaxed DNA-binding specificity are critical for PML/
RARA-induced immortalization. Proc Natl Acad Sci U S A 103: 9238–9243.
9. Hauksdottir H, Privalsky ML (2001) DNA recognition by the aberrant retinoic
acid receptors implicated in human acute promyelocytic leukemia. Cell Growth
Differ 12: 85–98.
10. Jeanne M, Lallemand-Breitenbach V, Ferhi O, Koken M, Le Bras M, et al.
(2010) PML/RARA oxidation and arsenic binding initiate the antileukemia
response of As2O3. Cancer Cell 18: 88–98.
11. Zhu J, Nasr R, Peres L, Riaucoux-Lormiere F, Honore N, et al. (2007) RXR is
an essential component of the oncogenic PML/RARA complex in vivo. Cancer
Cell 12: 23–35.
12. Grimwade D, Mistry AR, Solomon E, Guidez F (2010) Acute promyelocytic
leukemia:a paradigmfordifferentiationtherapy. Cancer Treat Res145:219–235.
13. Licht JD, Chomienne C, Goy A, Chen A, Scott AA, et al. (1995) Clinical and
molecular characterization of a rare syndrome of acute promyelocytic leukemia
associated with translocation (11;17). Blood 85: 1083–1094.
14. Petrie K, Zelent A, Waxman S (2009) Differentiation therapy of acute myeloid
leukemia: past, present and future. Curr Opin Hematol 16: 84–91.
15. Grignani F, De Matteis S, Nervi C, Tomassoni L, Gelmetti V, et al. (1998)
Fusion proteins of the retinoic acid receptor-alpha recruit histone deacetylase in
promyelocytic leukaemia. Nature 391: 815–818.
16. He LZ, Guidez F, Tribioli C, Peruzzi D, Ruthardt M, et al. (1998) Distinct
interactions of PML-RARalpha and PLZF-RARalpha with co- repressors
determine differential responses to RA in APL. Nat Genet 18: 126–135.
17. Boukarabila H, Saurin AJ, Batsche E, Mossadegh N, van Lohuizen M, et al.
(2009) The PRC1 Polycomb group complex interacts with PLZF/RARA to
mediate leukemic transformation. Genes Dev 23: 1195–1206.
18. Lin RJ, Nagy L, Inoue S, Shao W, Miller WH, Jr., et al. (1998) Role of the
histone deacetylase complex in acute promyelocytic leukaemia. Nature 391:
811–814.
19. Guidez F, Parks S, Wong H, Jovanovic JV, Mays A, et al. (2007) RARalpha-
PLZF overcomes PLZF-mediated repression of CRABPI, contributing to
retinoid resistance in t(11;17) acute promyelocytic leukemia. Proc Natl Acad
Sci U S A 104: 18694–18699.
20. Ruthardt M, Testa U, Nervi C, Ferrucci PF, Grignani F, et al. (1997) Opposite
effects of the acute promyelocytic leukemia PML-retinoic acid receptor alpha
(RAR alpha) and PLZF-RAR alpha fusion proteins on retinoic acid signalling.
Mol Cell Biol 17: 4859–4869.
21. Benoukraf T, Cauchy P, Fenouil R, Jeanniard A, Koch F, et al. (2009) CoCAS: a
ChIP-on-chip analysis suite. Bioinformatics 25: 954–955.
22. Barna M, Merghoub T, Costoya JA, Ruggero D, Branford M, et al. (2002) Plzf
mediates transcriptional repression of HoxD gene expression through chromatin
remodeling. Dev Cell 3: 499–510.
23. Moog-Lutz C, Peterson EJ, Lutz PG, Eliason S, Cave-Riant F, et al. (2001)
PRAM-1 is a novel adaptor protein regulated by retinoic acid (RA) and
promyelocytic leukemia (PML)-RA receptor alpha in acute promyelocytic
leukemia cells. J Biol Chem 276: 22375–22381.
24. Park DJ, Vuong PT, de Vos S, Douer D, Koeffler HP (2003) Com-
parative analysis of genes regulated by PML/RAR alpha and PLZF/RAR
alpha in response to retinoic acid using oligonucleotide arrays. Blood 102:
3727–3736.
25. Guibal FC, Moog-Lutz C, Smolewski P, Di Gioia Y, Darzynkiewicz Z, et al.
(2002) ASB-2 inhibits growth and promotes commitment in myeloid leukemia
cells. J Biol Chem 277: 218–224.
26. Rice KL, Hormaeche I, Doulatov S, Flatow JM, Grimwade D, et al. (2009)
Comprehensive genomic screens identify a role for PLZF-RARalpha as a positive
regulator of cell proliferation via direct regulation of c-MYC. Blood 114: 5499–5511.
27. Paietta E (2003) Expression of cell-surface antigens in acute promyelocytic
leukaemia. Best Pract Res Clin Haematol 16: 369–385.
28. Abbas S, Lugthart S, Kavelaars FG, Schelen A, Koenders JE, et al. (2010)
Acquired mutations in the genes encoding IDH1 and IDH2 both are recurrent
aberrations in acute myeloid leukemia: prevalence and prognostic value. Blood
116: 2122–2126.
29. Paschka P, Schlenk RF, Gaidzik VI, Habdank M, Kronke J, et al. (2010) IDH1
and IDH2 mutations are frequent genetic alterations in acute myeloid leukemia
and confer adverse prognosis in cytogenetically normal acute myeloid leukemia
with NPM1 mutation without FLT3 internal tandem duplication. J Clin Oncol
28: 3636–3643.
30. Yuki Y, Imoto I, Imaizumi M, Hibi S, Kaneko Y, et al. (2004) Identification of a
novel fusion gene in a pre-B acute lymphoblastic leukemia with t(1;19)(q23;p13).
Cancer Sci 95: 503–507.
31. O’Neil J, Look AT (2007) Mechanisms of transcription factor deregulation in
lymphoid cell transformation. Oncogene 26: 6838–6849.
32. Lin HK, Bergmann S, Pandolfi PP (2004) Cytoplasmic PML function in TGF-
beta signalling. Nature 431: 205–211.
33. Lin HK, Bergmann S, Pandolfi PP (2005) Deregulated TGF-beta signaling in
leukemogenesis. Oncogene 24: 5693–5700.
34. Xu S, Furukawa T, Kanai N, Sunamura M, Horii A (2005) Abrogation of
DUSP6 by hypermethylation in human pancreatic cancer. J Hum Genet 50:
159–167.
35. Okudela K, Yazawa T, Woo T, Sakaeda M, Ishii J, et al. (2009) Down-
regulation of DUSP6 expression in lung cancer: its mechanism and potential role
in carcinogenesis. Am J Pathol 175: 867–881.
Characterization of Genome-Wide PLZF/RARA Targets
PLoS ONE | www.plosone.org 10 September 2011 | Volume 6 | Issue 9 | e2417636. Villa R, Pasini D, Gutierrez A, Morey L, Occhionorelli M, et al. (2007) Role of
the polycomb repressive complex 2 in acute promyelocytic leukemia. Cancer
Cell 11: 513–525.
37. Kamashev D, Vitoux D, de The ´ H (2004) PML-RARA-RXR oligomers mediate
retinoid and rexinoid/cAMP cross-talk in acute promyelocytic leukemia cell
differentiation. J Exp Med 199: 1163–1174.
38. Delacroix L, Moutier E, Altobelli G, Legras S, Poch O, et al. (2009) Cell-specific
interaction of retinoic acid receptors with target genes in mouse embryonic
fibroblasts and embryonic stem cells. Mol Cell Biol.
39. Huang da W, Sherman BT, Lempicki RA (2009) Systematic and integrative
analysis of large gene lists using DAVID bioinformatics resources. Nat Protoc 4:
44–57.
40. Bolstad BM, Irizarry RA, Astrand M, Speed TP (2003) A comparison of
normalization methods for high density oligonucleotide array data based on
variance and bias. Bioinformatics 19: 185–193.
41. Saeed AI, Sharov V, White J, Li J, Liang W, et al. (2003) TM4: a free, open-
source system for microarray data management and analysis. Biotechniques 34:
374–378.
Characterization of Genome-Wide PLZF/RARA Targets
PLoS ONE | www.plosone.org 11 September 2011 | Volume 6 | Issue 9 | e24176